Equities research analysts expect Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to post $0.27 earnings per share for the current quarter, according to Zacks Investment Research. Eight analysts have made estimates for Neurocrine Biosciences’ earnings. The highest EPS estimate is $0.64 and the lowest is $0.02. Neurocrine Biosciences reported earnings of ($0.07) per share in the same quarter last year, which would suggest a positive year over year growth rate of 485.7%. The business is expected to announce its next quarterly earnings report on Tuesday, July 30th.
On average, analysts expect that Neurocrine Biosciences will report full-year earnings of ($0.08) per share for the current financial year, with EPS estimates ranging from ($0.56) to $0.82. For the next financial year, analysts expect that the business will report earnings of $3.01 per share, with EPS estimates ranging from $2.15 to $4.22. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that cover Neurocrine Biosciences.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Monday, April 29th. The company reported ($1.12) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.05) by ($0.07). Neurocrine Biosciences had a negative return on equity of 9.14% and a negative net margin of 7.56%. The business had revenue of $138.40 million during the quarter, compared to analysts’ expectations of $136.77 million. During the same quarter in the prior year, the firm earned ($0.47) EPS. The firm’s revenue for the quarter was up 94.7% compared to the same quarter last year.
In other Neurocrine Biosciences news, insider Haig P. Bozigian sold 66,667 shares of the business’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $80.13, for a total transaction of $5,342,026.71. Following the completion of the sale, the insider now owns 164,415 shares of the company’s stock, valued at $13,174,573.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Haig P. Bozigian sold 34,547 shares of the business’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $75.51, for a total value of $2,608,643.97. The disclosure for this sale can be found here. Insiders have sold 142,732 shares of company stock valued at $11,388,472 in the last three months. 4.30% of the stock is currently owned by corporate insiders.
A number of large investors have recently added to or reduced their stakes in NBIX. Nordea Investment Management AB lifted its position in shares of Neurocrine Biosciences by 1.2% in the first quarter. Nordea Investment Management AB now owns 38,996 shares of the company’s stock worth $3,435,000 after buying an additional 465 shares in the last quarter. BlueMountain Capital Management LLC raised its position in Neurocrine Biosciences by 314.7% during the first quarter. BlueMountain Capital Management LLC now owns 63,570 shares of the company’s stock valued at $5,601,000 after purchasing an additional 48,240 shares during the period. Kore Private Wealth LLC purchased a new stake in Neurocrine Biosciences during the first quarter valued at approximately $29,000. PointState Capital LP purchased a new stake in Neurocrine Biosciences during the first quarter valued at approximately $581,000. Finally, M&T Bank Corp raised its position in Neurocrine Biosciences by 7.8% during the first quarter. M&T Bank Corp now owns 3,224 shares of the company’s stock valued at $285,000 after purchasing an additional 232 shares during the period. 96.14% of the stock is owned by institutional investors and hedge funds.
Shares of NBIX stock traded down $0.16 during mid-day trading on Tuesday, hitting $83.92. The company’s stock had a trading volume of 509,256 shares, compared to its average volume of 645,076. Neurocrine Biosciences has a 52-week low of $64.72 and a 52-week high of $126.98. The company has a debt-to-equity ratio of 0.96, a current ratio of 8.79 and a quick ratio of 8.61. The stock has a market capitalization of $7.66 billion, a P/E ratio of 381.45 and a beta of 1.46.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.
Read More: Dividend Aristocrat Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.